Dynavax Technologies Corporation (DVAX)
NASDAQ: DVAX · IEX Real-Time Price · USD
11.54
-0.14 (-1.20%)
May 2, 2024, 12:55 PM EDT - Market open

Dynavax Technologies Revenue

In the year 2023, Dynavax Technologies had annual revenue of $232.28M, a decrease of -67.86%. Revenue in the quarter ending December 31, 2023 was $55.60M, a -69.87% decrease year-over-year.

Revenue (ttm)
$232.28M
Revenue Growth
-67.86%
P/S Ratio
6.57
Revenue / Employee
$569,324
Employees
408
Market Cap
1.51B USD

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 2023232.28M-490.40M-67.86%
Dec 31, 2022722.68M283.24M64.45%
Dec 31, 2021439.44M392.89M844.00%
Dec 31, 202046.55M11.33M32.18%
Dec 31, 201935.22M27.02M329.60%
Dec 31, 20188.20M7.87M2,407.03%
Dec 31, 2017327.00K-10.72M-97.04%
Dec 31, 201611.04M6.99M172.67%
Dec 31, 20154.05M-6.98M-63.29%
Dec 31, 201411.03M-219.00K-1.95%
Dec 31, 201311.25M1.54M15.82%
Dec 31, 20129.71M-11.90M-55.06%
Dec 31, 201121.61M-2.34M-9.75%
Dec 31, 201023.95M-16.37M-40.60%
Dec 31, 200940.32M3.22M8.69%
Dec 31, 200837.09M23.00M163.21%
Dec 31, 200714.09M9.25M190.76%
Dec 31, 20064.85M-9.81M-66.93%
Dec 31, 200514.66M-157.00K-1.06%
Dec 31, 200414.81M13.99M1,693.22%
Dec 31, 2003826.00K-601.00K-42.12%
Dec 31, 20021.43M-932.00K-39.51%
Dec 21, 20012.36M305.00K14.85%
Dec 31, 20002.05M--
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
Warby Parker 669.77M
InMode 492.05M
ADMA Biologics 258.22M
LeMaitre Vascular 193.48M
Ardelyx 124.46M
Arcus Biosciences 117.00M
Protagonist Therapeutics 60.00M
Revenue Rankings